Denali Therapeutics Inc (DNLI)
16.27
+0.12
(+0.74%)
USD |
NASDAQ |
May 02, 11:02
Denali Therapeutics Net Income (Quarterly): -119.47M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -119.47M |
September 30, 2023 | -99.35M |
June 30, 2023 | 183.38M |
March 31, 2023 | -109.78M |
December 31, 2022 | -98.68M |
September 30, 2022 | -103.30M |
June 30, 2022 | -58.79M |
March 31, 2022 | -65.22M |
December 31, 2021 | -75.26M |
September 30, 2021 | -84.59M |
June 30, 2021 | -60.69M |
March 31, 2021 | -70.04M |
December 31, 2020 | 244.88M |
September 30, 2020 | -58.23M |
June 30, 2020 | -58.76M |
Date | Value |
---|---|
March 31, 2020 | -56.76M |
December 31, 2019 | -54.02M |
September 30, 2019 | -46.26M |
June 30, 2019 | -58.34M |
March 31, 2019 | -38.99M |
December 31, 2018 | 77.53M |
September 30, 2018 | -35.37M |
June 30, 2018 | -54.72M |
March 31, 2018 | -23.68M |
December 31, 2017 | -22.89M |
September 30, 2017 | -21.84M |
June 30, 2017 | -22.13M |
March 31, 2017 | -21.32M |
December 31, 2016 | -19.35M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-119.47M
Minimum
Dec 2023
244.88M
Maximum
Dec 2020
-44.70M
Average
-60.69M
Median
Jun 2021
Net Income (Quarterly) Benchmarks
Halozyme Therapeutics Inc | 85.39M |
AIM ImmunoTech Inc | -12.58M |
Perspective Therapeutics Inc | -24.68M |
Protalix BioTherapeutics Inc | -6.044M |
Armata Pharmaceuticals Inc | -19.85M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 132.57M |
EPS Diluted (Quarterly) | -0.86 |
Enterprise Value | 1.268B |
Earnings Yield | -6.64% |
Normalized Earnings Yield | -5.962 |